Federated Hermes’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$866M Buy
3,980,171
+181,959
+5% +$40.4M 1.41% 5
2025
Q4
$868M Sell
3,798,212
-227,773
-6% -$51.9M 1.45% 6
2025
Q3
$932M Buy
4,025,985
+607,653
+18% +$124M 1.65% 4
2025
Q2
$635M Buy
3,418,332
+134,942
+4% +$25.1M 1.19% 6
2025
Q1
$688M Buy
3,283,390
+716,468
+28% +$139M 1.48% 4
2024
Q4
$456M Buy
2,566,922
+697,643
+37% +$128M 1% 9
2024
Q3
$369M Buy
1,869,279
+48,758
+3% +$9.1M 0.81% 18
2024
Q2
$312M Buy
1,820,521
+32,708
+2% +$5.42M 0.74% 26
2024
Q1
$326M Sell
1,787,813
-504,840
-22% -$87M 0.75% 25
2023
Q4
$355M Buy
2,292,653
+437,672
+24% +$63.8M 0.88% 18
2023
Q3
$277M Buy
1,854,981
+12,663
+0.7% +$1.86M 0.74% 24
2023
Q2
$248M Sell
1,842,318
-784,659
-30% -$115M 0.62% 31
2023
Q1
$419M Sell
2,626,977
-29,143
-1% -$4.46M 1.05% 13
2022
Q4
$429M Buy
2,656,120
+228,140
+9% +$35M 1.19% 10
2022
Q3
$326M Sell
2,427,980
-183,878
-7% -$26.4M 0.95% 14
2022
Q2
$400M Sell
2,611,858
-1,289,081
-33% -$197M 1.09% 8
2022
Q1
$632M Sell
3,900,939
-1,264,452
-24% -$184M 1.43% 3
2021
Q4
$699M Buy
5,165,391
+117,783
+2% +$13.9M 1.3% 4
2021
Q3
$544M Sell
5,047,608
-3,309
-0.1% -$378K 1.04% 9
2021
Q2
$569M Sell
5,050,917
-81,755
-2% -$9.21M 1.06% 7
2021
Q1
$555M Sell
5,132,672
-54,512
-1% -$5.83M 1.08% 6
2020
Q4
$556M Sell
5,187,184
-405,822
-7% -$39M 1.14% 7
2020
Q3
$490M Sell
5,593,006
-973,543
-15% -$91.7M 1.15% 8
2020
Q2
$645M Sell
6,566,549
-1,596,712
-20% -$141M 1.6% 2
2020
Q1
$622M Sell
8,163,261
-293,090
-3% -$25M 1.83% 3
2019
Q4
$749M Sell
8,456,351
-154,167
-2% -$12.8M 1.67% 4
2019
Q3
$652M Buy
8,610,518
+631,857
+8% +$43.3M 1.6% 4
2019
Q2
$580M Sell
7,978,661
-17,629
-0.2% -$1.39M 1.41% 8
2019
Q1
$644M Buy
7,996,290
+1,623,690
+25% +$133M 1.59% 8
2018
Q4
$587M Buy
6,372,600
+2,702,968
+74% +$238M 1.6% 9
2018
Q3
$347M Buy
3,669,632
+1,469,718
+67% +$139M 0.81% 21
2018
Q2
$204M Sell
2,199,914
-620,922
-22% -$60.6M 0.6% 28
2018
Q1
$267M Sell
2,820,836
-3,377,602
-54% -$371M 0.78% 24
2017
Q4
$599M Sell
6,198,438
-4,437,598
-42% -$418M 1.69% 12
2017
Q3
$945M Sell
10,636,036
-4,493,187
-30% -$342M 2.71% 4
2017
Q2
$1.1B Sell
15,129,223
-326,904
-2% -$22M 3.16% 1
2017
Q1
$1.01B Buy
15,456,127
+398,077
+3% +$25M 2.87% 3
2016
Q4
$943M Buy
15,058,050
+94,872
+0.6% +$5.79M 2.83% 3
2016
Q3
$944M Buy
14,963,178
+1,647,581
+12% +$107M 2.72% 5
2016
Q2
$824M Buy
13,315,597
+1,911,448
+17% +$116M 2.41% 7
2016
Q1
$651M Buy
11,404,149
+11,116,084
+3,859% +$620M 2.02% 9
2015
Q4
$17.1M Sell
288,065
-364,082
-56% -$21M 0.05% 305
2015
Q3
$35.5M Sell
652,147
-493,241
-43% -$32.1M 0.11% 179
2015
Q2
$77M Buy
1,145,388
+1,926
+0.2% +$126K 0.23% 85
2015
Q1
$66.9M Buy
1,143,462
+565,894
+98% +$34.2M 0.2% 100
2014
Q4
$37.8M Sell
577,568
-87,997
-13% -$5.55M 0.12% 166
2014
Q3
$38.4M Sell
665,565
-3,652,275
-85% -$203M 0.12% 163
2014
Q2
$244M Buy
4,317,840
+268,769
+7% +$14.1M 0.76% 26
2014
Q1
$208M Sell
4,049,071
-4,148,900
-51% -$210M 0.7% 27
2013
Q4
$433M Sell
8,197,971
-457,695
-5% -$22.5M 1.5% 10
2013
Q3
$387M Sell
8,655,666
-186,676
-2% -$8.27M 1.49% 11
2013
Q2
$366M Buy
+8,842,342
New +$387M 1.45% 12

Other funds holding ABBV

Federated Hermes's ABBV Position: Q1 2026 in Review

Federated Hermes increased its AbbVie (ABBV) stake by 4.8% in Q1 2026, buying an estimated $40.4M and bringing the position to 3,980,171 shares worth $866M. The position accounts for 1.41% of the portfolio, ranked #5.

Federated Hermes first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.1B in Q2 2017. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Federated Hermes held 3,980,171 shares of AbbVie worth $866M as of Q1 2026.
  • Federated Hermes bought 181,959 AbbVie shares in Q1 2026, an estimated $40.4M.
  • AbbVie made up 1.41% of Federated Hermes's portfolio in Q1 2026, its #5 holding.
  • Federated Hermes first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Federated Hermes's AbbVie position peaked at $1.1B in Q2 2017.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.